Posted by Michael Wonder on 26 Jul 2022
ERC granted FDA fast track designation for sitoiganap in patients with recurrent glioblastoma
26 July 2022 - ERC Belgium today announced that the U.S. FDA has granted fast track designation to Sitoiganap (Gliovac or ERC1671) ERC’s cell-based immunotherapy for the treatment of glioblastoma, the most aggressive form of brain cancer.
Sitoiganap is an advanced immunotherapy derived from brain tumour tissue that is surgically removed from patients with recurrent glioblastoma multiforme.
